Heterozygous pathogenic germline variants in PALB2 have been associated with an increased risk of breast cancer which approaches that seen with variants in BRCA2, in the order of 48–63%, with increased risks for those patients with a family history of breast cancer [101,102,103,104,105]. The gene discussed is BRCA2; the disease is breast carcinoma.